The Carolina Breast Cancer Study (CBCS) is a comprehensive, interdisciplinary investigation into the causes of breast cancer in African American and white women. A major focus of the CBCS is to understand genetic susceptibility. Our goal is to conduct the first comprehensive, population-based study of genetic risk factors for in situ and invasive breast cancer in African American and white women. Our recent results have shown that germline mutations in BRCA genes are rare in breast cancer patients. Common inherited polymorphisms in metabolism genes play a role in a much larger number of cases. To date, we have investigated hormone metabolism, carcinogen metabolism, and cell cycle control. We propose here to expand our study of genetic susceptibility to include DNA repair genes, and potential interactions between these genes and exposure to environmental factors. Our preliminary data indicates that polymorphisms in the base excision repair gene, XRCC1, and the double-strand break repair gene, XRCC3, are susceptibility genes for breast cancer. During Phase 1 of the CBCS (1993-1996), 861 cases of invasive breast cancer and 790 population controls were enrolled. During Phase 2 (1996-2000), 890 cases of invasive breast cancer, 514 cases of in situ breast cancer, and 1232 controls were enrolled. After enrolling additional controls, the total number of participants is expected to be 2265 cases and 2086 controls. African Americans comprise 44 percent of invasive cases and 21 percent of in situ cases. Controls are frequency matched to cases based upon age and race. CBCS participants complete in-depth interviews covering known and potential risk factors for breast cancer. Blood samples are collected for extraction of lymphocyte DNA. DNA samples and exposure histories are available from 2147 cases and 2021 controls. The current proposal provides for statistical and laboratory analyses using previously collected DNA samples and exposure information from the CBCS.
The Specific Aims are to conduct high throughput genotyping for single nucleotide polymorphisms in genes involved in the principal DNA repair Pathways: Base excision repair (XRCC], APEI, HOGG], Pol Beta); nucleotide excision repair (XPA, XPD, XPF, ERCC1); double strand break repair (XRCC3, XRCC4); nonhomologous end joining (DNA PK, DNA ligase/); direct repair (MGMT, AGT). Main effects for each genetic locus will be estimated, as well as the combined effects of multiple genes (gene-gene interaction) and the joint effects of genetic and environmental factors (gene-environment interaction). The study will provide important information regarding genetic susceptibility to breast cancer in African American and white women, and help to clarify the role of ionizing radiation, smoking and other environmental exposures in the etiology of breast cancer. In addition, we propose to extend our data collection and obtain updated treatment and outcome information on breast cancer cases. This information will allow us to evaluate novel hypotheses related to the role of DNA repair in response to adjuvant chemotherapy and radiation treatment, and to generate pilot data for subsequent grant applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058223-09A1
Application #
6547495
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1992-09-30
Project End
2006-07-31
Budget Start
Budget End
Support Year
9
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381

Showing the most recent 10 out of 598 publications